Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin

Details for Australian Patent Application No. 2005274927 (hide)

International Classifications

Event Publications

8 February 2007 PCT application entered the National Phase

PCT publication WO2006/020049 Priority application(s): WO2006/020049

6 October 2011 Assignment before Grant

AMR Technology, Inc.; Bristol-Myers Squibb Company The application has been assigned to Bristol-Myers Squibb Company; Albany Molecular Research, Inc. 2006

3 November 2011 Application Accepted

Published as AU-B-2005274927

1 March 2012 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.